Used in pharmaceutical research as a potent inhibitor of Bruton's tyrosine kinase (BTK), a specific kinase enzyme involved in inflammatory and oncogenic signaling pathways, particularly B-cell receptor signaling. Demonstrates potential in the development of targeted therapies for autoimmune diseases and certain cancers, such as B-cell malignancies including leukemia, due to its ability to modulate cellular proliferation and immune response. Its structure allows for high selectivity and improved pharmacokinetic properties, making it a valuable scaffold in drug design for oral small-molecule therapeutics. Currently under investigation for efficacy and safety in human trials, aiming for cancer treatments with high specificity and reduced side effects compared to traditional chemotherapy.